Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Theraclone Sciences
About
Theraclone Sciences is a biotech company developing novel therapeutic antibodies for the treatment of infectious diseases and inflammation.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $8M
- Industries
- Biotechnology,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2004
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 25, 2013 | Series B | $8M | 2 | — | — | Detail |
| Sep 8, 2011 | Series B | $10.60M | 1 | — | — | Detail |
| Mar 17, 2010 | Series Unknown | $1.50M | 1 | — | — | Detail |
| Mar 19, 2007 | Series B | $29M | 1 |
ARCH Venture Partners
|
— | Detail |
| Mar 3, 2006 | Series A | $4.60M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
ARCH Venture Partners
|
— | Series B |
Versant Ventures
|
— | Series B |
